GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (NYSE:NVO) » Definitions » Cyclically Adjusted PS Ratio

NVO (Novo Nordisk AS) Cyclically Adjusted PS Ratio : 12.63 (As of Jul. 02, 2025)


View and export this data going back to 1981. Start your Free Trial

What is Novo Nordisk AS Cyclically Adjusted PS Ratio?

As of today (2025-07-02), Novo Nordisk AS's current share price is $69.82. Novo Nordisk AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $5.53. Novo Nordisk AS's Cyclically Adjusted PS Ratio for today is 12.63.

The historical rank and industry rank for Novo Nordisk AS's Cyclically Adjusted PS Ratio or its related term are showing as below:

NVO' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 8.17   Med: 12.01   Max: 31.25
Current: 11.73

During the past years, Novo Nordisk AS's highest Cyclically Adjusted PS Ratio was 31.25. The lowest was 8.17. And the median was 12.01.

NVO's Cyclically Adjusted PS Ratio is ranked worse than
93.76% of 737 companies
in the Drug Manufacturers industry
Industry Median: 2.17 vs NVO: 11.73

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Novo Nordisk AS's adjusted revenue per share data for the three months ended in Mar. 2025 was $2.545. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $5.53 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novo Nordisk AS Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Novo Nordisk AS's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Cyclically Adjusted PS Ratio Chart

Novo Nordisk AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.42 16.05 17.24 22.72 17.43

Novo Nordisk AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.39 30.25 22.84 17.43 12.57

Competitive Comparison of Novo Nordisk AS's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk AS's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's Cyclically Adjusted PS Ratio falls into.


;
;

Novo Nordisk AS Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Novo Nordisk AS's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=69.82/5.53
=12.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Novo Nordisk AS's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=2.545/120.2000*120.2000
=2.545

Current CPI (Mar. 2025) = 120.2000.

Novo Nordisk AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.788 100.300 0.944
201509 0.784 100.200 0.940
201512 0.827 99.800 0.996
201603 0.797 100.200 0.956
201606 0.816 100.600 0.975
201609 0.819 100.200 0.982
201612 0.833 100.300 0.998
201703 0.818 101.200 0.972
201706 0.881 101.200 1.046
201709 0.863 101.800 1.019
201712 0.904 101.300 1.073
201803 0.913 101.700 1.079
201806 0.884 102.300 1.039
201809 0.897 102.400 1.053
201812 0.942 102.100 1.109
201903 0.927 102.900 1.083
201906 0.953 102.900 1.113
201909 0.941 102.900 1.099
201912 1.020 102.900 1.191
202003 1.063 103.300 1.237
202006 0.966 103.200 1.125
202009 1.049 103.500 1.218
202012 1.130 103.400 1.314
202103 1.168 104.300 1.346
202106 1.160 105.000 1.328
202109 1.227 105.800 1.394
202112 1.270 106.600 1.432
202203 1.363 109.900 1.491
202206 1.288 113.600 1.363
202209 1.336 116.400 1.380
202212 1.514 115.900 1.570
202303 1.701 117.300 1.743
202306 1.755 116.400 1.812
202309 1.872 117.400 1.917
202312 2.154 116.700 2.219
202403 2.131 118.400 2.163
202406 2.198 118.500 2.230
202409 2.380 118.900 2.406
202412 2.702 118.900 2.732
202503 2.545 120.200 2.545

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novo Nordisk AS  (NYSE:NVO) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Novo Nordisk AS Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk AS Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.